What IL-17 Inhibitor can do for your PsA and AxSpA Patients

Introduction

Despite the availability of treat-to-target strategies, many psoriatic arthritis (PsA) patients are undertreated. Tight control across multiple domains of PsA improves clinical outcomes and QoL. Axial spondyloarthritis (axSpA) refers to the inflammation of the axial skeleton and encompasses two subtypes of the same disease: AS/r-axSpA and nr-axSpA. Lack of effective alternative therapies in axSpA leads to inadequate response or failure to maintain response.

Objectives

To provide information on the role of IL-17 inhibition in the treatment of AS/r-axSpA. Physicians will share their experiences through real life cases on the role of IL-17 inhibition in PsA management.

This Course For :

Resident / Fellow
Physician
Clinical Pharmacy

Sponsored by :

Price

Course Fee

FREE

FREE
VAT Included
See Registration Policies, Cancellations & Refunds

Contact Information

Organization : Virtual Medical Academy
Phone : 920008161
Email : info@medicalacademy.org

  • 24 Feb 2021    To    24 Feb 2021
  • 09:00 PM  To  10:30 PM
  • Certificate Available
  • Online Click Here
  • 147
  Add to Calendar 02/24/2021 09:00 PM 02/24/2021 10:30 PM Asia/ Riyadh What IL-17 Inhibitor can do for your PsA and AxSpA Patients What IL-17 Inhibitor can do for your PsA and AxSpA Patients https://medicalacademy.org/portal/event/view/1388